Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Demand remained firm in the decorative applications field of Industrial Materials and in medical-device and pharmaceutical CDMO services in Medical, while demand for tablets in Devices declined significantly. In addition, an impairment loss on USM goodwill was recognized following the discovery of inappropriate accounting treatment at USM and the transfer of its shares.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | 96,033 Millions of yen (YoY -1.0%) |
| Operating profit | -4,500 Millions of yen |
| Ordinary income | -4,806 Millions of yen |
| Profit attributable to owners of the parent | -5,473 Millions of yen |
| Net income per share | −¥115.44 |
| Equity ratio | End of the current fiscal period 45.4 / End of previous period 46.1 |
| Total assets | 252,642 Millions of yen |
| Net assets | 115,744 Millions of yen |
| Cash flows from operating activities | 5,553 Millions of yen |
| Cash flows from investing activities | -11,647 Millions of yen |
| Cash flows from financing activities | -4,210 Millions of yen |
| Cash and cash equivalents at end of period | 29,993 Millions of yen |
| Full-year earnings forecast | Net Sales 195,000 Millions of yen (YoY +0.1%) / Operating profit -3,300 Millions of yen / Ordinary income -4,400 Millions of yen / Net income -6,200 Millions of yen |
| Revision to Earnings Forecast | Net Sales Not disclosed → 195,000 Millions of yen / Operating profit Not disclosed → -3,300 Millions of yen / Ordinary income Not disclosed → -4,400 Millions of yen / Net income Not disclosed → -6,200 Millions of yen |
| Annual Dividend Forecast | ¥50 → ¥50（0.0%） |
| Segment revenue | Industrial Materials 41,147 Millions of yen (YoY +9.5%) / Devices 22,868 Millions of yen (YoY -23.1%) / Medical 29,034 Millions of yen (YoY +8.0%) |
| Segment profit | Industrial Materials 1,519 Millions of yen (YoY -27.9%) / Devices -6,050 Millions of yen / Medical 1,905 Millions of yen (YoY +11.1%) |
| Depreciation and amortization | 5,223 Millions of yen |
| Impairment loss | 6,759 Millions of yen |
| Breakdown of extraordinary income (loss) | Impairment loss 6,759 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | 1 new company (USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY), 0 companies excluded |
| Material subsequent events | The transfer of USM shares was decided on 4 September 2026, and an impairment loss on USM goodwill was recognized on 30 September 2026. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 48,016,100 |
| Treasury Shares at Period-End | 570,837 |
| Factors Behind Changes in Business Performance | Demand remained firm in the decorative applications field of Industrial Materials and in medical-device and pharmaceutical CDMO services in Medical, while demand for tablets in Devices declined significantly. In addition, an impairment loss on USM goodwill was recognized following the discovery of inappropriate accounting treatment at USM and the transfer of its shares. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Devices, demand for tablets declined significantly. In addition, inappropriate accounting treatment was discovered at USM HEALTHCARE MEDICAL DEVICES FACTORY JOINT STOCK COMPANY before its acquisition, resulting in the recognition of an impairment loss on USM goodwill. In Industrial Materials, higher production-related costs also weighed on operating profit.